Healthcare DIVE May 7, 2018
Dive Brief:
- Geisinger will begin offering patients whole exome sequencing, or genomic sequencing, at no cost, CEO David Feinberg announced Sunday during a keynote session at HLTH 2018 in Las Vegas.
- The initiative builds off the integrated health system’s collaboration with Regeneron Pharmaceuticals, which began in 2013 to sequence the DNA of MyCode Community Health Initiatives participants. More than 200,000 patients are participating in the MyCode program, which aims for earlier detection and identification of conditions like cancer and heart disease.
- Geisinger will sign up 1,000 patients in the new program over the next six months to roll out DNA sequencing as routine care practice, the company said.
Today's Sponsors
Today's Sponsor